Advertisement
EW vs ISRG
Which Stock Would AI Choose? Edwards Lifesciences (EW) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- EW and ISRG are both premium medical-device leaders, but they compete in distinct markets: structural heart therapy versus robotic-assisted surgery.
- EW delivered double-digit revenue growth and raised its full-year outlook, with shares up roughly 14% over the past three months.
- ISRG has fallen about 25% year to date despite strong fundamentals, pressured by competition and moderating procedure-growth concerns.
- Valuations diverge meaningfully: EW trades near 28–29 times forward earnings, while ISRG trades at roughly 38–48 times, a premium even after its decline.
- Relative momentum currently favors EW, while ISRG offers a durable, recurring-revenue business model with about 86% of sales recurring.
Introduction
Edwards Lifesciences (EW) and Intuitive Surgical (ISRG) sit at the heart of two of healthcare's most compelling growth stories. Edwards is the global leader in structural heart innovation, best known for transcatheter aortic valve replacement (TAVR), while Intuitive pioneered robotic-assisted surgery with its da Vinci platform. Although both operate in the medical-device sector, their recent price behavior has diverged sharply, making this a useful case study in market positioning and relative performance. Growth-oriented investors evaluating premium healthcare names, as well as traders comparing momentum against valuation, may find this stock comparison especially relevant in the current environment.
EW Overview and Recent Performance
Edwards Lifesciences (EW) is a structural heart specialist focused on treating aortic, mitral, and tricuspid valve disease. Its largest franchise, TAVR, pairs with a fast-growing transcatheter mitral and tricuspid therapies (TMTT) segment and a surgical structural heart business. In recent quarters, the company has shown broad-based strength: TAVR sales grew at a double-digit pace, TMTT revenues expanded by roughly 45% year over year, and surgical sales advanced steadily. Management raised its full-year revenue guidance as a result.
This execution has translated into positive market sentiment. EW shares have climbed about 14% over the past three months, outperforming the broader S&P 500 and reflecting confidence in raised 2026 expectations. The stock trades at a forward price-to-earnings (P/E) multiple near 28–29 times, a premium to the market that reflects its growth profile. Key influences on sentiment include strong TAVR demand, scaling of newer therapies such as PASCAL, EVOQUE, and SAPIEN M3, and a clean balance sheet with roughly $2.9 billion in cash against about $600 million in debt.
ISRG Overview and Recent Performance
Intuitive Surgical (ISRG) is the pioneer and dominant player in robotic-assisted surgery, with its da Vinci surgical systems and the Ion endoluminal system for lung biopsy. Its business model blends system placements with a large recurring stream of instruments, accessories, and services, which now accounts for roughly 86% of revenue. Recent quarters have featured revenue growth above 20% and adjusted operating margins near 39%, with a growing installed base of more than 11,000 systems.
Despite these fundamentals, ISRG shares have declined about 25% year to date after peaking above $600 earlier in the year. Sentiment has been weighed down by moderating da Vinci procedure growth, rising competition from Chinese manufacturers and larger rivals, and softer bariatric volumes tied to GLP-1 weight-loss drug adoption. The stock has, however, rebounded in recent weeks as investors weigh the durability of its recurring revenue and the rollout of the newer da Vinci 5 platform against a still-elevated valuation near 38–48 times earnings.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively monitor and trade thousands of different tickers across varied strategies and timeframes. Because not every bot suits every market regime, Tickeron curates only the most effective performers into its Trending AI Robots section, where the best and most suitable bots for current market conditions are highlighted. Each bot carries its own trading style, strategy, timeframe, performance history, statistics, and portfolio of tickers, giving users a range of approaches to review. Whether you are focused on the medical-device names covered here or a broader watchlist, exploring this curated selection can help you see how systematic, AI-driven strategies are currently positioned. Visit the Trending AI Robots page to explore the available bots and their current signals.
Head-to-Head Comparison
The clearest contrast between these two companies is their recent market trajectory. EW carries positive momentum, with accelerating growth across multiple product lines and a management team repeatedly raising guidance. ISRG, by contrast, faces a valuation reset even as its underlying business remains profitable and cash-generative.
Their business models also differ in structure. Edwards derives most revenue from implantable heart-valve technologies, a capital-light model tied closely to procedural volumes and clinical evidence. Intuitive blends capital-equipment sales with a razor-and-blades style recurring revenue stream that grows as its installed base expands. This gives ISRG a more predictable revenue base but also exposes it to hospital capital-budget cycles and competition in a way that differs from Edwards' clinical-evidence-driven adoption.
Risk profiles diverge as well. Edwards faces foreign-exchange headwinds, ongoing litigation, and competitive threats in TAVR, while Intuitive contends with slowing procedure growth, Chinese and U.S. competitors, and margin pressure from tariffs and input costs. On valuation, EW appears more reasonably priced relative to its growth, while ISRG commands a higher multiple that leaves less room for disappointment despite its recent pullback.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor EW in the current environment. Edwards exhibits stronger trend consistency, clearer near-term catalysts from raised guidance and product scaling, and healthier relative momentum over recent months. Intuitive Surgical retains an attractive recurring-revenue model and long-term growth runway, but its still-elevated valuation, decelerating procedure growth, and competitive pressures introduce greater uncertainty. The assessment is probabilistic rather than definitive: while the balance of momentum, stability, and positioning currently tilts toward Edwards, conditions can shift, and neither name is without risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EW is a Buy and ISRG is a Hold.
EW in upward trend: price rose above 50-day moving average on October 21, 2026
EW moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on EW as a result. In 55 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for EW just turned positive on October 14, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
The 10-day moving average for EW crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +3.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in 172 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for EW moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 16 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
EW broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EW entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.995) is normal, around the industry mean (4.201). P/E Ratio (52.879) is within average values for comparable stocks, (1.335). Projected Growth (PEG Ratio) (1.852) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (7.974) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ISRG sees MACD Histogram crosses below signal line
ISRG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 31 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 13 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 35%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 58 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 170 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.400) is normal, around the industry mean (4.882). P/E Ratio (48.870) is within average values for comparable stocks, (38.076). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
EW | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 73 | |
SMR RATING 1..100 | 72 | 51 | |
PRICE GROWTH RATING 1..100 | 28 | 47 | |
P/E GROWTH RATING 1..100 | 8 | 79 | |
SEASONALITY SCORE 1..100 | 50 | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ISRG's Valuation (79) in the Medical Specialties industry is in the same range as EW (91). This means that ISRG’s stock grew similarly to EW’s over the last 12 months.
ISRG's Profit vs Risk Rating (73) in the Medical Specialties industry is in the same range as EW (100). This means that ISRG’s stock grew similarly to EW’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as EW (72). This means that ISRG’s stock grew similarly to EW’s over the last 12 months.
EW's Price Growth Rating (28) in the Medical Specialties industry is in the same range as ISRG (47). This means that EW’s stock grew similarly to ISRG’s over the last 12 months.
EW's P/E Growth Rating (8) in the Medical Specialties industry is significantly better than the same rating for ISRG (79). This means that EW’s stock grew significantly faster than ISRG’s over the last 12 months.
| EW | ISRG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 35% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 66% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 63% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 66% |
| Advances ODDS (%) | 3 days ago 59% | 9 days ago 66% |
| Declines ODDS (%) | 24 days ago 60% | 4 days ago 61% |
| BollingerBands ODDS (%) | 2 days ago 59% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 64% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EW’s FA Score shows that 2 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
- EW’s FA Score: 2 green, 3 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EW’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 3 bullish TA indicator(s).
- EW’s TA Score: 5 bullish, 5 bearish.
- ISRG’s TA Score: 3 bullish, 5 bearish.
Price Growth
EW (@Medical/Nursing Services) experienced а +3.30% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -4.48% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.04%. For the same industry, the average monthly price growth was -8.74%, and the average quarterly price growth was -9.59%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.77%. For the same industry, the average monthly price growth was -3.29%, and the average quarterly price growth was +8.60%.
Reported Earning Dates
EW is expected to report earnings on Nov 04, 2026.
ISRG is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Medical/Nursing Services (+0.04% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-1.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement